Leerink Partners analyst Daina Graybosch has maintained their bullish stance on BNTX stock, giving a Buy rating on March 13.
Daina Graybosch’s rating is based on a combination of factors that highlight both the challenges and opportunities for BioNTech SE. Despite the recent sell-off following the company’s earnings disclosure, which indicated potential negative year-over-year growth by FY2025, there remains optimism for future growth driven by oncology advancements. The company is expected to experience short-term volatility due to political and regulatory uncertainties in the U.S., but positive developments in their oncology pipeline could refocus attention on growth drivers.
On the oncology front, BioNTech’s strategic development of BNT327, particularly in first-line non-small cell lung cancer (NSCLC), is promising. The company’s approach to separately address squamous and non-squamous populations, along with insights from the newly initiated Phase 2 study, strengthens their position. Additionally, significant oncology catalysts, such as the overall survival outcomes from Akeso’s HARMONi-2 trial and top-line results from the HARMONi-6 trial, are anticipated to play a crucial role in BioNTech’s growth trajectory.
Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, Arcus Biosciences, and Fate Therapeutics. According to TipRanks, Graybosch has an average return of -15.9% and a 31.41% success rate on recommended stocks.
In another report released on March 13, Citi also initiated coverage with a Buy rating on the stock with a $145.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com